A Randomized Study Comparing Once-Daily and Thrice-Daily Naftopidil 75 mg/Day for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia

Akiou Okumura, Shinji Tsuritani, Tetsuo Nozaki, Hitomi Kimura, Taizo Kazama

Abstract


Background: The efficacy and tolerability of naftopidil 75 mg administered once daily (OD) in the evening (group O) were compared to those of naftopidil 25 mg thrice daily (TID), given in the morning, afternoon and evening (group T), for lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). The factors predicting the efficacy of each dosage regimen were also examined.

Methods: The participants were 101 patients with LUTS/BPH who were randomly administered naftopidil for 8 weeks in either group O or group T. Inclusion criteria were international prostate symptom score (IPSS) greater than or equal to 8 and IPSS quality of life (IPSS-QoL) greater than or equal to 3.

Results: IPSS total score, IPSS-QoL and the BPH impact index were all significantly improved compared to baseline for both groups at 8 weeks after treatment. Voided volume, maximum flow rate and average flow rate were significantly improved compared to baseline only for group O at 8 weeks after treatment. The effectiveness rate based on the criteria for treatment efficacy of the Japanese clinical practice guideline for voiding dysfunction was not significantly different between the two groups. There was no independent predictive factor for the efficacy of naftopidil in group O, but prostate volume and symptom severity were identified as predictive factors in group T. The rate of adverse events was not significantly different between the two groups.

Conclusions: The overall efficacy of naftopidil 75 mg/day given OD was approximately equal to that of 75 mg/day TID, but OD therapy was objectively more effective. LUTS/BPH patients with large prostate volume should be given OD therapy because the therapy is not affected by the severity of subjective symptoms or prostate volume.




World J Nephrol Urol. 2014;3(2):72-82
doi: http://dx.doi.org/10.14740/wjnu169e

Keywords


Benign prostatic hyperplasia; Dosage method; Naftopidil; Predictive factor

Full Text: HTML PDF
 

Browse  Journals  

     

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 

 

 

 

World Journal of Nephrology and Urology, quarterly, ISSN 1927-1239 (print), 1927-1247 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.wjnu.org   editorial contact: editor@wjnu.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada
© Elmer Press Inc. All Rights Reserved.